FDA approves Moderna’s first mRNA influenza vaccine for adults 50 and older

The FDA approved Moderna’s mFLUSIVA for adults 50 and older, making it the first authorized seasonal flu vaccine based on mRNA technology. The agency granted traditional approval for ages 50–64 and accelerated approval for people 65 and older, subject to a confirmatory study.

How outlets across the spectrum are covering this story. We link out — headlines belong to their publishers; the summary above is ours.

• ClickOnDetroit (WDIV) · center · factuality: medium-high
  New kind of flu shot is on the way as the FDA approves Moderna's mRNA-based vaccine
• The Guardian · left · factuality: high
  The mRNA technology behind Moderna’s Covid vaccine reaches the flu
• PBS NewsHour · center · factuality: very-high
  New kind of flu shot is on the way as the FDA approves Moderna's mRNA-based vaccine
• NPR · lean-left · factuality: very-high
  A new flu vaccine geared to older people is coming soon
• The Washington Times · right · factuality: medium
  FDA approves first mRNA flu vaccine after reversing its own rejection